Pfizer's Celebrex Showed Cardiovascular Risk In 1999 Alzheimer's Study
This article was originally published in The Pink Sheet Daily
Executive Summary
A study of celecoxib in Alzheimer's disease patients showed a statistically significant increase in cardiovascular events versus placebo. The study data are posted on PhRMA's clinicalstudyresults.org website, but Public Citizen alleges Pfizer recently revised the posting and questions when the data were submitted to FDA.
You may also be interested in...
GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome
GlaxoSmithKline will continue development of its Phase II COX-2 inhibitor regardless of the outcome of an FDA advisory committee meeting on the safety of the class, CEO J.P. Garnier told investors
GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome
GlaxoSmithKline will continue development of its Phase II COX-2 inhibitor regardless of the outcome of an FDA advisory committee meeting on the safety of the class, CEO J.P. Garnier told investors
Pfizer's McKinnell Cancels National Press Club Speech
Exec was expected to discuss health care reform, and was likely to have been asked about cardiovascular safety of Celebrex and Bextra. McKinnell canceled the speech due to the flu, which he caught in Asia while assessing Pfizer's tsunami relief efforts.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: